These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
172 related items for PubMed ID: 12113135
1. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma. Bendandi M. Expert Rev Anticancer Ther; 2001 Jun; 1(1):65-72. PubMed ID: 12113135 [Abstract] [Full Text] [Related]
2. Anti-idiotype vaccines for human follicular lymphoma. Bendandi M. Leukemia; 2000 Aug; 14(8):1333-9. PubMed ID: 10942225 [Abstract] [Full Text] [Related]
3. Therapeutic lymphoma vaccines: importance of T-cell immunity. Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW. Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622 [Abstract] [Full Text] [Related]
4. The role of idiotype vaccines in the treatment of human B-cell malignancies. Bendandi M. Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042 [Abstract] [Full Text] [Related]
5. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study. Yáñez R, Barrios Y, Ruiz E, Cabrera R, Díaz-Espada F. J Immunother; 2008 Apr; 31(3):310-2. PubMed ID: 18317357 [Abstract] [Full Text] [Related]
7. Translational development of vaccination strategies in follicular NHL. Sakamaki I, Qin H, Kwak LW. Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625 [Abstract] [Full Text] [Related]
9. [Past, present and future of anti-idiotype vaccination]. Rodríguez Calvillo M, Inogés S, López Díaz de Cerio A, Zabalegui N, Panizo C, Hernández M, Pérez Calvo J, Prósper F, Melero I, Sánchez-Ibarrola A, Rocha E, Bendandi M. Rev Med Univ Navarra; 2004 Jun; 48(3):14-23. PubMed ID: 15622921 [Abstract] [Full Text] [Related]
10. Vaccines for lymphomas: idiotype vaccines and beyond. Houot R, Levy R. Blood Rev; 2009 May; 23(3):137-42. PubMed ID: 18951668 [Abstract] [Full Text] [Related]
13. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Ruffini PA, Neelapu SS, Kwak LW, Biragyn A. Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812 [Abstract] [Full Text] [Related]
17. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. J Clin Oncol; 2004 Dec 01; 22(23):4717-24. PubMed ID: 15483014 [Abstract] [Full Text] [Related]
19. The anti-idiotype vaccines for immunotherapy. Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA. Curr Opin Mol Ther; 2001 Feb 01; 3(1):63-9. PubMed ID: 11249733 [Abstract] [Full Text] [Related]
20. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM. Immunol Rev; 2008 Apr 01; 222():316-27. PubMed ID: 18364011 [Abstract] [Full Text] [Related] Page: [Next] [New Search]